NCT03804580View on ClinicalTrials.gov

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

June 1, 2025

Study Completion Date

December 31, 2025

Conditions
Lung Cancer
Interventions
DRUG

osimertinib

Non-randomized trial, all patients receive therapy

Trial Locations (10)

Unknown

Aarhus University Hospital, Aarhus

Herlev Hospital, Copenhagen

Rigshospitalet, Copenhagen

Odense University Hospital, Odense

National Cancer Institute, Vilnius

Lund University Hospital, Lund

Karolinska University Hospital, Stockholm

N-3004

Drammen Hospital - Vestre Viken HF, Drammen

N-0450

Oslo University Hospital - Ullevaal, Oslo

N-7008

St Olavs Hospital, Trondheim

All Listed Sponsors
lead

Vestre Viken Hospital Trust

OTHER

NCT03804580 - First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter